Acurx Pharmaceuticals Narrows Q1 Net Loss to $1.68M, Advances Clinical Pipeline
Summary
Acurx Pharmaceuticals reported its first-quarter 2026 results, showing a net loss of $(1.68M) and EPS of $(0.62). This represents a 22% improvement in net loss year-over-year. The company also provided positive operational updates, including the completion of a pooled Phase 2 study for ibezapolstat with a 96% clinical cure rate and the initiation of planning for a Phase 3 strategy. This earnings report follows the company's last 10-K, which included a going concern warning and highlighted the need for dilutive financing, which was addressed by approximately $2.5M in capital raised in April 2026. For a micro-cap biotech with a going concern, the narrowing net loss, continued clinical progress, and successful capital raise are material updates that provide crucial insight into the company's operational stability and development trajectory. Investors should monitor the progress of Phase 3 planning and future financing requirements.
At the time of this announcement, ACXP was trading at $2.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $1.33 to $21.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.